There is a potential risk of early structural valve deterioration with the Abbott Trifecta valve and Trifecta valve with glide technology (Trifecta GT), the US Food and Drug Administration (FDA) says ...
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...
Newly Published Data Indicates St. Jude Medical Trifecta Heart Valve Closely Resembles the Hemodynam
Newly Published Data IndicatesSt. Jude Medical Trifecta Heart Valve Closely Resembles the Hemodynamic Performance of a Natural, Healthy Heart Valve Study in The Journal of Thoracic and Cardiovascular ...
There is potentially a higher risk of early structural valve deterioration (SVD)—within 5 years—with Abbott’s Trifecta valves than with other comparable SAVR bioprostheses, according to an alert ...
Next-generation design offers physicians most advanced pericardial aortic tissue valve in the U.S. ST. PAUL, Minn., St. Jude Medical, Inc., a global medical device company, today announced that it has ...
St Jude Medical Inc, a Minnesota-based global medical device company, on Wednesday announced regulatory approval from the Japanese Ministry of Health, Labor and Welfare and the launch of the Trifecta ...
In replacement aortic valve procedures, bioprosthetic valves have become increasingly more common than mechanical replacements, since those made out of animal tissue are less likely to cause blood ...
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in ...
ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the European launch of the company’s most advanced tissue valve — the Trifecta™ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results